Design of experiments

Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2020 Financial Results and Recent Business Highlights

Retrieved on: 
Tuesday, May 12, 2020

A Phase 2 clinical study with PL9643 for dry eye disease started in January 2020, and active patients continue treatment and monthly clinic visits.

Key Points: 
  • A Phase 2 clinical study with PL9643 for dry eye disease started in January 2020, and active patients continue treatment and monthly clinic visits.
  • Data readout is targeted for the fourth quarter of calendar year 2020.
  • Totaloperating expenses for the quarter ended March 31, 2020 were $5.7 million compared to $5.8 million for the comparable quarter of 2019.
  • The difference in financial results between the three months ended March 31, 2020 and 2019 was mainly attributable to the increase in other income, net.

Clinical Trial Data Analytics Helped a Pharma Company to Determine Chance of Disease Relapse | A Quantzig Success Story

Retrieved on: 
Monday, May 11, 2020

As a part of its new healthcare provider analytics article series, Quantzig, a premier analytics services provider, today announced the completion of its recent case study- How Clinical Trial Data Analytics Helped a Leading Global Pharma Company to Determine Chance of Disease Relapse

Key Points: 
  • As a part of its new healthcare provider analytics article series, Quantzig, a premier analytics services provider, today announced the completion of its recent case study- How Clinical Trial Data Analytics Helped a Leading Global Pharma Company to Determine Chance of Disease Relapse
    This press release features multimedia.
  • Clinical trial data analysis requires tested statistical methods that have to be specified with the regulatory authorities before the trial even begins.
  • Clinical trial data analysis done using data analytics tools can help pharmaceutical companies to understand the epidemiology landscape and develop an effective enrollment forecast, says a clinical data analytics expert at Quantzig.
  • Our clinical trial data analysis solutions help companies to analyze performance with access to critical trial data in real-time.

Choroidal Neovascularization Clinical Trials by G7 Countries: Proportion of Choroidal Neovascularization to Ophthalmology Clinical Trials - ResearchAndMarkets.com

Retrieved on: 
Monday, May 11, 2020

The "Choroidal Neovascularization Global Clinical Trials Review, H1, 2020" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Choroidal Neovascularization Global Clinical Trials Review, H1, 2020" clinical trials has been added to ResearchAndMarkets.com's offering.
  • The clinical trial report, "Choroidal Neovascularization Global Clinical Trials Review, H1, 2020" provides top line data relating to the clinical trials on Choroidal Neovascularization.
  • The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.
  • The report also provides prominent drugs for in-progress trials (based on number of ongoing trials).

Global HIV Treatment Clinical Trial Pipeline Products by Company

Retrieved on: 
Monday, May 11, 2020

DUBLIN, May 11, 2020 /PRNewswire/ -- The "Global HIV Treatment Clinical Trial Pipeline Highlights - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, May 11, 2020 /PRNewswire/ -- The "Global HIV Treatment Clinical Trial Pipeline Highlights - 2020" report has been added to ResearchAndMarkets.com's offering.
  • The 'HIV Treatment Pipeline Highlights - 2020' report provides the most up-to-date information on key pipeline products in the global HIV Treatment market.
  • It covers emerging therapies for HIV Treatment in active clinical development stages including early and late-stage clinical trials.
  • The report provides HIV Treatment pipeline products by clinical trial stages including both early and late-stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Greenphire Enhances Its Participant Payment and Reimbursement Solution to Further Support Remote Clinical Trials

Retrieved on: 
Monday, May 11, 2020

To help keep trials active and patients engaged during trial disruption, Greenphire , the global leader in financial software for clinical trials, today announced that it has enhanced its award-winning payment and reimbursement solution, ClinCard, to include additional capabilities to support decentralized clinical trials due to COVID-19 interruptions.

Key Points: 
  • To help keep trials active and patients engaged during trial disruption, Greenphire , the global leader in financial software for clinical trials, today announced that it has enhanced its award-winning payment and reimbursement solution, ClinCard, to include additional capabilities to support decentralized clinical trials due to COVID-19 interruptions.
  • "As the landscape for clinical trials evolves, we're beginning to see a need for remote payment capabilities.
  • In addition to these new enhancements to ClinCard, Greenphire also recently announced additional capabilities to ConneX, our global clinical trial patient travel solution.
  • The choice of industry leaders worldwide, Greenphire provides better performance and better data, resulting in better trials.

Global Dry Eye Market, Pipeline, Epidemiology, Competitive Analysis, Drug Sales and Shares (2016-2024) - ResearchAndMarkets.com

Retrieved on: 
Monday, May 11, 2020

The "Global Dry Eye Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Dry Eye Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • This research report provides comprehensive insights into the Dry Eye pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • The research analyzes and forecasts the Dry Eye market size and drug sales.
  • Dry Eye pipeline: Find out drugs in clinical trials for the treatment of Dry Eye by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Dry Eye drugs: Identify key drugs marketed and prescribed for Dry Eye in the US, including trade name, molecule name, and company
    Dry Eye market valuations: Find out the market size for Dry Eye drugs in 2019 by countries.

Evelo Biosciences Reports First Quarter Financial Results and Business Highlights

Retrieved on: 
Monday, May 11, 2020

ET

Key Points: 
  • ET
    CAMBRIDGE, Mass., May 11, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today reported financial results and business highlights for the first quarter 2020.
  • Evelo today announced the results of two additional clinical studies with EDP1815.
  • Evelo expects to present results of this study, including the TNBC cohort, at a future medical conference.
  • Evelo Biosciences, Inc.is a clinical stage biotechnology company developing oral biologics that act on SINTAX with systemic therapeutic effects.

Global Brain Cancer Clinical Trials Review: Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status - ResearchAndMarkets.com

Retrieved on: 
Monday, May 11, 2020

The "Brain Cancer Global Clinical Trials Review, H1, 2020" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Brain Cancer Global Clinical Trials Review, H1, 2020" clinical trials has been added to ResearchAndMarkets.com's offering.
  • The "Brain Cancer Global Clinical Trials Review, H1, 2020" report provides top line data relating to the clinical trials on Brain Cancer.
  • The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.
  • The report also provides prominent drugs for in-progress trials (based on number of ongoing trials).

Myelofibrosis Global Clinical Trials Review: Top Companies Participating in Myelofibrosis Therapeutics Clinical Trials - ResearchAndMarkets.com

Retrieved on: 
Monday, May 11, 2020

The "Myelofibrosis Global Clinical Trials Review, H1, 2020" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Myelofibrosis Global Clinical Trials Review, H1, 2020" clinical trials has been added to ResearchAndMarkets.com's offering.
  • The clinical trial report "Myelofibrosis Global Clinical Trials Review, H1, 2020" provides top line data relating to the clinical trials on Myelofibrosis.
  • The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.
  • The report also provides prominent drugs for in-progress trials (based on number of ongoing trials).

FDA Approves First Therapy for Patients with Lung and Thyroid Cancers with a Certain Genetic Mutation or Fusion

Retrieved on: 
Friday, May 8, 2020

Retevmo is the first therapy approved specifically for cancer patients with the RET gene alterations.

Key Points: 
  • Retevmo is the first therapy approved specifically for cancer patients with the RET gene alterations.
  • "The FDA is committed to reviewing treatments like Retevmo that are targeted to specific subsets of patients with cancer."
  • The FDA approved Retevmo on the results of a clinical trial involving patients with each of the three types of tumors.
  • During the clinical trial, patients received 160 mg Retevmo orally twice daily until disease progression or unacceptable toxicity.